Measuring factor VIII activity in patients with severe haemophilia A treated with extended half-life concentrates – comparison of selected assay results

Czech version

Authors: M.- Prudková ^{1 3}; P. Smejkal ^1,3; D. Chytrá ^1,3; J. Zavřelová ^1,3; G.- Romanová ^{1 3}; M. Penka ^1,2; A. Buliková ^1,2
Authors‘ workplace: Oddělení klinické hematologie, FN Brno ¹; Interní hematologická a onkologická klinika LF MU a FN Brno ²; Katedra laboratorních metod, LF MU, Brno ³
Published in: Transfuze Hematol. dnes,30, 2024, No. 4, p. 243-252.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz16

Overview

Introduction: Optimal substitutional treatment includes measuring FVIII activity (FVIII: C) using the one-stage clotting assay (OSA) or chromogenic substrate assay (CSA). However, with the advent of FVIII concentrates with an extended half-life, discrepancies between methods have increased due to modifications of the FVIII molecule. Aim: Evaluation of OSA and CSA discrepancy in patients treated with extended half--life FVIII concentrates. Method: FVIII: C measurement by OSA with reagents Cephascreen® (Diagnostica Stago) and Pathromtin® SL (Siemens Healthineers) and by CSA BIOPHEN^TM FVIII: C (Hyphen BioMed) in patients treated with efmoroctocog alfa, rurioctocog alfa pegol, turoctocog alfa pegol and damoctocog alfa pegol. Results: The results of both methods correlated well for efmoroctocog alfa, the differences being up to 21%. The results of rurioctocog alfa pegol in the range of 15–200% were slightly lower using OSA with both reagents, on average by 11% and 18%, while the results up to 10% were higher using OSA with an average difference of 54% for Cephascreen® and up to 75% for Pathromtin® SL. The results of turoctocog alfa pegol were lower using OSA in the range of 15–200%, on average by 36% and 25%. The samples with FVIII: C above 10% of damoctocog alfa pegol were slightly higher using OSA (Cephascreen® by 18%), but samples up to 10% were significantly higher, with Cephascreen® on average by 91% and by 100% with Pathromtin® SL. Conclusions: OSA Cephascreen® or Pathromtin® SL and CSA Hyphen correlate excellently in the case of efmoroctocog alfa. Of the other concentrates, the results correlate excellently in the case of rurioctocog alfa pegol (only Cephascreen®) and damoctocog alfa pegol, and only for FVIII: C > 10%.

Keywords:

haemophilia A – FVIII activity – EHL concentrates

Sources

1. Young GA, Perry DJ; for The International Prophylaxis Study Group (IPSG). Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J Thromb Haemost. 2019; 17 : 567–573.

2. Marlar RA, Strandberg K, Shima M, Adcock DA. Clinical utility and impact of the use of the chromogenic vs one‐stage factor activity assays in haemophilia A and B. Eur J Haematol. 2020; 104 : 3–14.

3. Pruthi RK. Laboratory monitoring of new hemostatic agents for hemophilia. Semin Hematol. 2016; 53 : 28–34.

4. Smejkal P, Blatný J, Hajšmanová Z, et al. Konsenzuální doporučení Českého národního hemofilického programu (ČNHP) pro diagnostiku a léčbu pacientů s hemofilií, vydání 3., rok 2021. Transfuze Hematol Dnes. 2021; 27 (1): 73–90.

5. Gray E, Kitchen S, Bowyer A, et al. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020; 26 : 6–16.

6. Jeanpierre E, Pouplard C, Lasne D, et al. Factor VIII and IX assays for post‐infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT). Eur J Haematol. 2020; 105 : 103–115.

7. Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: Impact of factor and non‐factor replacement therapy on coagulation assays. J Thromb Haemost. 2020; 18 : 1242–1255.

8. Augustsson C, Norström E, Andersson NG, Zetterberg E, Astermark J, Strandberg K. Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre –⁠ and postinfusion samples. Res Pract Thromb Haemost. 2020; 4 : 1114–1120.

9. Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practise: guidance from UKHCDO. Haemophilia. 2016; 22 : 487–498.

10. Hubbard AR, Dodt J, Lee T, et al. Recommendations onthe potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost. 2013; 11 : 988–989.

11. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14 : 248–261.

12. Škorňová I, Slavík L, et al. Faktory vnitřní koagulační cesty (FVIII, FIX, FXI a FXII). In: Hemostáza: laboratorní metody, jejich využití a interpretace ve vybraných klinických situacích. 2. vyd. Olomouc, Univerzita Palackého v Olomouci, 2021; 66-73.

13. Srivasta A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. https: //onlinelibrary.wiley.com/doi/10.1111/hae.14046, přístup 25.10.2023.

14. Bowyer AE, Duncan EM, Antovic JP. Role of chromogenic assays in haemophilia A and B diagnosis. Haemophilia. 2018; 24 : 578–583.

15. Souhrn údajů o přípravku Elocta®. https: // www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_cs.pdf, přístup 3.11.2023

16. Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018; 9 : 295–308.

17. Souhrn údajů o přípravku Adynovi®. https: // www.ema.europa.eu/en/documents/product-information/adynovi-epar-product-information_cs.pdf, přístup 3.11.2023

18. Turecek PL, Romender-Finger S, Apostol C, et al. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII: C aktivity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. Haemophilia. 2016; 22 : 957–965.

19. Souhrn údajů o přípravku Esperoct®. https: // www.ema.europa.eu/en/documents/product-information/esperoct-epar-product-information_cs.pdf, přístup 3.11.2023

20. Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT®) assay performance: Implications for postadministration monitoring. Haemophilia. 2020; 26 : 156–163.

21. Church N, Leong L, Katterle Y, et al. Factor VIII activity of BAY 94‐9027 is accurately measured with most commonly used assays: Results from an international laboratory study. Haemophilia. 2018; 24 : 823–832.

22. Souhrn údajů o přípravku Jivi®. https: //www.ema.europa.eu/en/documents/product-information/jivi-epar-product-information_cs.pdf, přístup 3.11.2023

23. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016; 15 : 155–163.

24. Lowe A, Jennings I, Kitchen S. One stage and chromogenic FVIII assay results at trough levels: a UK national external quality assessment scheme for blood coagulation (UK NEQAS BC) exercise. Haemophilia. 2020; 26 : 27.

25. Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII aktivity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clottting and chromogenic assay kits: a two-centre study. Haemophilia. 2017; 23 : 458–465.

26. Pickering W, Hansen M, Kjalke M, Ezban M. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8‐GP. J Thromb Haemost. 2016; 14 : 1579–1587.

27. Van den Bossche D, Peerlinck K, Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hem. 2018; 40 (Suppl. 1): 21–29.

28. Cinotti S, Paladino E, Morfini M. Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent. J Thromb Haemost. 2006; 4 : 828–833.

PODÍL AUTORŮ NA PŘÍPRAVĚ RUKOPISU

MP –⁠ laboratorní diagnostika, napsání rukopisu

SP, RG –⁠ léčba pacientů, revize rukopisu

CHD, ZJ –⁠ laboratorní diagnostika, revize rukopisu

ZJ –⁠ laboratorní diagnostika, revize rukopisu

PM, BA –⁠ revize rukopisu

ČESTNÉ PROHLÁŠENÍ

Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.

PODĚKOVÁNÍ

Podpořeno MZ ČR-RVO (FNBr, 65269705) a grantem MUNI/A/1558/2023.

Do redakce doručeno dne: 31. 1. 2024.

Přijato po recenzi dne: 8. 7. 2024.

Mgr. Marie Prudková

Oddělení klinické hematologie

FN Brno

Jihlavská 340/20

625 00 Brno

e-mail: prudkova.marie@fnbrno.cz